![Laura Stoppel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 33 280 $ al 31/05/2026
Laura Stoppel currently works at Acumen Pharmaceuticals, Inc., as Independent Director from 2020, Nimbus Therapeutics LLC, as Director from 2020, CellCentric Ltd., as Director from 2024, Verdiva Bio, Inc., as Director from 2024, Artiva Biotherapeutics, Inc., as Independent Director from 2020, Indapta Therapeutics, Inc., as Director from 2022, International Rett Syndrome Foundation, as Director from 2023, RA Capital Management LP, as Partner from 2024, and RA Capital Management LP (Private Equity), as Principal from 2020.
Dr. Stoppel received her undergraduate degree in 2008 from Harvard University and doctorate degree in 2016 from Massachusetts Institute of Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 03/06/2026 | 12.800 ( 0,02 % ) | 33 280 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Director/Miembro de la Junta | 01/06/2020 |
| ACUMEN PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/11/2020 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Inversor de Capital Privado | 01/12/2020 |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical stage biotech company that develops molecule medicines for diseases like cancer, immune disorders and metabolic conditions | Director/Miembro de la Junta | 01/10/2020 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Director/Miembro de la Junta | 01/01/2022 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Analyst-Equity | 01/10/2016 |
International Rett Syndrome Foundation | Director/Miembro de la Junta | 01/07/2023 |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule inhibitors for cancer | Director/Miembro de la Junta | 01/07/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Acumen Pharmaceuticals, Inc.
 Acumen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops medicines and diagnostics for Alzheimer's disease | Health Technology |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
Nimbus Therapeutics LLC
Nimbus Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical stage biotech company that develops molecule medicines for diseases like cancer, immune disorders and metabolic conditions | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule inhibitors for cancer | Health Technology |
International Rett Syndrome Foundation | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
